Impact of the Novel UC-TREAT Diet on the Gut Microbiome and Its Acceptability in Healthy Adults and Adults With Quiescent Ulcerative Colitis
Launched by UNIVERSITY OF GLASGOW · May 21, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a new diet called the UC-TREAT diet on the gut microbiome, which is the community of bacteria in our intestines. The trial involves both healthy adults and adults with quiescent (inactive) Ulcerative Colitis (UC), and it will last for 25 days. Participants will first spend 10 days following their usual diet, and then for the next 15 days, they will switch to a diet rich in high-fiber foods, fermented foods, berries, and a multivitamin. Throughout the study, participants will provide blood, stool, and urine samples, and complete questionnaires about their symptoms and quality of life.
To be eligible for the trial, participants with Ulcerative Colitis must be at least 16 years old and have a confirmed diagnosis of UC, while healthy controls must also be 16 or older and willing to follow the diet. Certain health conditions and recent medication changes may exclude individuals from participating. At the end of the study, participants will share their thoughts on how acceptable they found the diet. This trial aims to understand how diet affects gut health and could help improve dietary recommendations for people with Ulcerative Colitis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Individuals with Ulcerative Colitis:
- • Confirmed diagnosis of Ulcerative Colitis
- • ≥16 years of age
- • Motivated to follow the prescribed diet for the study period
- Healthy controls:
- • ≥16 years of age
- • Motivated to follow the prescribed diet for the study period
- Exclusion Criteria:
- Individuals with Ulcerative Colitis:
- • Self-reported active disease (SCCAI≥5) and/or a score ≥2 on any variable within SCCAI
- • Previous surgery related to their UC (e.g. colectomy)
- • Adjustment of medication dose in the previous month
- • Initiation of a new medication in the prior 3 months
- • BMI≥35kg/m2
- • Pregnancy or lactation
- • Regular use of pre/probiotic supplements
- • Antibiotics or steroid use in the past 2 months
- • Weight fluctuations ≥ 2kg in the past month
- • Dietary restrictions (vegetarian, vegan, gluten-free etc)
- • Participation in other interventional research.
- Healthy controls:
- • Regular use of medication or regular visits to a physician
- • History of gut surgery
- • BMI≥35kg/m2
- • Pregnancy or lactation
- • Regular use of pre/probiotic supplements
- • Antibiotics or steroid use in the past 2 months
- • Weight fluctuations ≥ 2kg in the past month
- • Dietary restrictions (vegetarian, vegan, gluten-free etc)
- • Participation in other interventional research.
About University Of Glasgow
The University of Glasgow is a prestigious academic institution renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive expertise in various fields of medicine and health sciences to design and conduct innovative clinical trials. With a strong focus on ethical standards and patient safety, the University of Glasgow collaborates with multidisciplinary teams and partners to translate research findings into practical applications, fostering advancements in medical knowledge and therapeutic interventions. Its dedication to excellence in research and education positions the university as a leader in clinical trial initiatives that aim to address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glasgow, , United Kingdom
Patients applied
Trial Officials
Konstantinos Gerasimidis
Principal Investigator
University of Glasgow
Athanasios Koutsos
Principal Investigator
University of Glasgow
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported